Proof-of-concept randomised, placebo-controlled trial (n=48) testing low-dose ketamine (0.2 mg/kg; possible escalation to 0.5 mg/kg) as an adjunct to propofol-based anaesthesia for ECT in adults with major depressive disorder.
Randomised, parallel-group study comparing propofol induction with adjunct low-dose ketamine versus propofol with saline placebo in patients referred for ECT for major depressive disorder; total sample n=48.
Patients receive ECT up to three times per week for a maximum of 12 treatments; outcomes include depressive symptoms (MADRS), recovery characteristics, vital signs, and adverse events; an interim analysis after 14 patients could trigger dose escalation to 0.5 mg/kg.
Propofol induction with addition of low-dose ketamine (0.2 mg/kg; possible escalation to 0.5 mg/kg per interim analysis).
Administered with usual propofol induction (0.75–1 mg/kg)
Propofol induction with normal saline placebo.
Normal saline administered with usual propofol induction